

AD _____

Award Number: W81XWH-11-1-0820

TITLE: Serotonin Signal Transduction in Two Groups of Autistic Patients

PRINCIPAL INVESTIGATOR: Mark M. Rasenick, PhD

CONTRACTING ORGANIZATION: University of Illinois at Chicago
Chicago, IL 60612-4305

REPORT DATE: October 2012

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2012		2. REPORT TYPE Annual		3. DATES COVERED 15 September 2011–14 September 2012	
4. TITLE AND SUBTITLE Serotonin Signal Transduction in Two Groups of Autistic Patients				5a. CONTRACT NUMBER W81XWH-11-1-0820	
				5b. GRANT NUMBER W81XWH-11-1-0820	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Mark M. Rasenick E-Mail: raz@jic.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Illinois at Chicago Chicago, IL 60612-4305				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT About 25-30% of patients with autism show high platelet serotonin while the rest have a normal serotonin level. Some in the high-serotonin group show defects in serotonin transporter (SERT), others do not. Furthermore, while treatment with selective serotonin uptake inhibitors (SSRI) is routine for autistic patients, therapeutic benefit is variable and unpredictable. We hypothesized that there is an essential difference in serotonin signal transduction between these two groups and that this could be exploited to determine therapeutic success and to identify new therapeutic complete targets.. Lymphoblasts were prepared from 6 high- and low-serotonin patients as well as controls and these will be used to determine the relationship between IS, serotonin levels and serotonin signaling. These cells, which are normally reserved for genetic studies, were probed for differences in serotonin signaling, and clear differences were seen both in response to serotonin and response to SSRI treatment. The most innovative aspect of this proposal is the development of lymphoblasts as a cellular model to explore the pharmacology and cell biology of autism. Lymphoblasts are made routinely from Autism patients seen at academic medical centers and they are used, almost exclusively, for genetic studies. The ability to use them as a predictive model for therapeutic response and as an experimental model to probe serotonin (or other neurotransmitter signaling) in autism is both innovative and potentially transformative.					
15. SUBJECT TERMS Autism, serotonin, G-protein, GPCR					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			Dr. Mark M. Rasenick
			UU		19b. TELEPHONE NUMBER (include area code) 312-996-6641

TABLE OF CONTENTS

Introduction.....	1
Body	1 - 2
Key Research Accomplishments.....	2 - 3
Reportable Outcomes.....	4
Conclusions	4
References	4 - 5

Annual Progress Report

INTRODUCTION

Distinct lines of neurochemical, behavioral, and now molecular genetic evidence implicate dysfunction of the serotonin system in autism spectrum disorders (ASD), and specifically in restricted and repetitive behaviors (RRBs). Discovery of elevated platelet serotonin (5HT) in ~25-30% of individuals with autism is one of the seminal findings in neuropsychiatric research.

Autism is the most heritable complex neuropsychiatric disorder, and platelet 5HT levels are also extremely heritable (Abney, et.al. 2001). Further, elevated platelet 5HT is associated with familial recurrence risk, both in autism and in obsessive compulsive disorder (OCD). The relationship between autism and OCD is reflected in correlations between restricted and repetitive behaviors (RRBs) in probands with autism and OC symptoms in their parents (Abramson, et.al. 2005). Rare mutations in the serotonin transporter (SERT) gene (SLC6A4) have recently been identified that display a common pattern of elevated 5HT transporter activity and produce a phenotype of autism with RRBs or OCD (Sutcliffe, et.al. 2005).

An index of Insistence on Sameness (IS) from the ADI-R (Shao, et.al, 2003) and from the RBS-R (Lam, et.al. 2007) captures the symptoms that are often most distressing to patients and their families, however, deciphering the relationships between autism and a dysregulated 5HT system requires critical neurochemical phenotypes that will allow the underlying common mechanisms to be elucidated. For example, studies of platelet 5HT levels in inbred and outbred populations pointed to the integrin $\beta 3$ gene (ITGB3) as a quantitative trait locus for platelet 5HT levels (Weiss, et.al, 2004). Further SERT and ITGB3 physically interact in the platelet, and that the absence of Itgb3 in mouse brain significantly diminishes SERT activity (Carneiro, et.al, 2008).

Other studies have found decreased 5HT_{2A} receptor binding in the platelet that correlates between boys with autism and their fathers and parallels decreased receptor binding in recent brain studies. We suggest a dysregulated 5HT system, IS, and autism susceptibility are related. Furthermore, we hypothesize that variation within components of the 5HT signaling system is likely to contribute to autism susceptibility as well.

BODY

Statement of Work

Weeks 1-16

Grow 10 lines each of normal and high-serotonin lymphoblasts from autistic subjects. Compare agonist (5HT₄ and 5HT₁ stimulation and inhibition of adenylyl cyclase and 5HT₂ stimulation of PLC β 1 from the two populations. Also compare receptor-activated GTP γ S binding between the two groups.

Weeks 16-40

Complete the rest of the cell lines from each group making necessary modification as learned from the initial studies. Treat cells with escitalopram or r-citalopram and test for increased coupling between G proteins and effector molecules

Weeks 40-52

Select 5 lines from each group and transfect with GFP-Gsa. Determine lipid raft distribution and changes in raft localization in response to agonist

Data are described below. We were not able to do more than 5 lines of each cell type, as the growth conditions were, initially, challenging. This was worked out and the cells are growing well and giving us good data (see below).

KEY RESEARCH ACCOMPLISHMENTS

Preliminary Data: Over 200 children and adolescents have been assessed with the research diagnostic tools, the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) at UIC as part of the UIC Autism Center of Excellence (UIC-ACE). Blood was sent to the NIMH genetics repository at Rutgers, where lymphoblast cell lines were established. We have grown cells from high 5HT/high IS and normal 5HT/moderate IS subjects and analyzed them as described below.

Our emphasis has been on the role of membrane microdomains (lipid rafts) in modulating G protein signaling (see Allen et.al, 2007), and a recent focus has been on 5HT_{4,6} and 7 receptors, which signal through Gs α . Gs α coupling to adenylyl cyclase is augmented when released from lipid rafts (Allen et.al, 2009). Further, Gs α is more highly ensconced in lipid rafts in certain psychiatric diseases, such as depression, and chronic treatment with antidepressants, including SSRIs, fosters translocation of Gs α to non-raft membrane domains (Zhang and Rasenick, 2010).

Future considerations: Lymphoblasts are not brains, and the translation to brains requires some faith on the part of both investigator and reviewer. Nonetheless, lymphocytes and platelets from patients with a number of psychiatric diseases have been used to search for biomarkers and establish altered receptor displays or signaling pathways. While viral transformation may change the cells, G-coupled protein receptor (GPCR) expression in lymphocytes and lymphoblasts are similar.

In order to address this concern, selected characterized cell lines will be reprogrammed, initially into pluripotent stem cells and then into neurons. This is no trivial exercise and there is some question that lymphoblasts can be infected with the "reprogramming" viral cassette (available from Sigma). We have been assured by Rudolph Jaenisch (personal communication) that this is indeed feasible (Staerk et.al., 2010) and Rusty Gage has told us that he will be glad to help us transform the induced pluripotent stem cells into neurons. We are aware that the efficiency of such an induction is very small, but if, indeed, the cell lines are useable, then the cell numbers are considerable. If not, we do have the ability to draw blood and collect lymphocytes from many of the subjects from whom we have lymphoblasts available.

By comparing lymphoblasts from the High- and Low-IS and high and low serotonin subjects, we hope to develop a clearer understanding of serotonin signaling in autism. Since many of the current drugs for autism influence the serotonin signaling system, it is thought that such an improved understanding will help us to develop more individualized therapy for these children and develop improved medications.




Figure 1 (top). Escitalopram translocates Gsα in cells obtained from High 5HT subjects. Lymphoblasts from High 5HT/High IS or Normal 5HT/moderate IS (two lines each) were grown in suspension and treated with escitalopram or control (r-citalopram, @10 μM) for 3days, harvested and membranes were prepared. Lipid raft fractions were prepared by sucrose density sedimentation and the extent of Gsα ensconsed in rafts (determined with quantitative immunoblots) is described in the figure. Escitalopram was effective in only in the high 5HT group. * p <0.01 ; High 5HT control vs Normal control p < 0.05

Figure 2 (bottom). Elevated response to 5HT4 and 5HT agonists in lymphoblasts from a high 5HT/high IS subject. Lymphoblasts from a high and normal 5HT subject were grown in suspension for 4 days, harvested and membranes were prepared and assayed for adenylyl cyclase in the presence of the indicated agonist (ser, 5HT; BIMU-B, 5HT4; WAY 408, 5HT6). Consistent with the results in figure 1, heightened responsiveness to Gs-coupled 5HT-activated adenylyl cyclase is seen in cells where Gsα is displaced from lipid rafts (where it couples more effectively with adenylyl cyclase). Assays were performed twice, in triplicate.

REPORTABLE OUTCOMES

Two abstracts have been presented concerning this work. One was at the Brain Research Foundation symposium and the other was at the Molecular Pharmacology Gordon Conference. Natalie Cook was the presenting author on each. She received a Carl Storm Minority Fellowship to present this work at the Gordon Conference.

Drs. Cook and Rasenick submitted a Letter of Intent to the Simons foundation for funds to continue this work. The letter of intent was accepted and they were asked to submit a full proposal. A decision is still pending.

CONCLUSION

Lymphoblasts had been collected from patients only to generate genetic material. We have demonstrated, for the first time, that lymphoblasts prepared from patient material, can be used as a cell biological model for disease, which will be useful for both understanding disease process and for providing model systems to test novel therapeutic mechanisms.

REFERENCES

- Abney M, McPeck MS, Ober C. Broad and narrow heritabilities of quantitative traits in a founder population. 2001 *Am J Hum Genet.* 68:1302-7.
- Allen J, Halverson-Tamboli, R and Rasenick MM. 2007. Lipid raft microdomains and neurotransmitter signaling. *Nature Reviews Neuroscience* 8:128-140.
- Allen, JA, Yu, J-Z., Dave, R.H., Bhatnagar, J., Roth, B.L. and Rasenick, M.M. 2009 "Caveolin-1 and lipid microdomains regulate Gs trafficking and attenuate Gs/adenylyl cyclase signaling" *Mol. Pharmacol* 76:1082-93.
- Carneiro AM, Cook EH, Murphy DL, Blakely RD. 2008 Interactions between integrin alpha1 beta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. *J Clin Invest.* 118:1544-52.
- Cook, E.H., Arora, R.C., Anderson, G.M., Berry-Kravis, E.M., Yan, S-y., Yeoh, H.C., Sklena, P.J., Charak, D.A., Leventhal, B.L. 1993: Platelet serotonin studies in familial hyperserotonemia of autism. *Life Sciences*, 52:2005-2015.
- Lam KS, Aman MG. The Repetitive Behavior Scale-Revised: independent validation in individuals with autism spectrum disorders. 2007 *J Autism Dev Disord.* 37:855-66.
- Lord, C.L., Cook, E.H., Leventhal, B.L., Amaral, D.G.: 2000 Minireview: Autism spectrum disorders. *Neuron*, 28:355-363.

- Shao Y, Cuccaro ML, Hauser ER, Raiford KL, Menold MM, Wolpert CM, Ravan SA, Elston L, Decena K, Donnelly SL, Abramson RK, Wright HH, DeLong GR, Gilbert JR, Pericak-Vance MA. 2003 Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. *Am J Hum Genet.* 72:539-48.
- Staerk,J, Dawiaty, M, Gao, Q, Maetzel, D, Hanna, J, Sommer, C., Mostoslavsky, G and Jaenisch, R (2010) Reprogramming of human peripheral blood cells into induced pluripotent stem cells. *Cell Stem Cell* 7:20-24
- Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, Jiang L, Li C, Folstein SE, Blakely RD. Allelic heterogeneity at the serotonin transporter locus(SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. 2005 *Am J Hum Genet.* 77:265-79.
- Zhang L and Rasenick M.M., 2010 Chronic treatment with escitalopram but not R-citalopram translocates Galpha s from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound. *J Pharmacol Exp Ther.* 332:977-984